Following a request from SMA Europe, Biogen has released the following community updates on:
- Access to Spinraza™ : 28 European countries now have access to Spinraza™ for 5q SMA Types I, II and III, via regular reimbursement but in some cases, including age restrictions. Additionally, in certain countries there are rare disease/ medical committees who apply further inclusion and exclusion clinical criteria. For more details, please see Biogen’s table, dated 9th September 2019.
- Update on Biogen’s ongoing trials in SMA: Please read an update from Biogen on the results of the NURTURE study recently presented at Cure SMA’s Annual Conference. The NURTURE study is an ongoing Phase 2, open-label study of 25 pre-symptomatic patients with SMA, who received their first dosing before six weeks of age.